Physician profile
Salim Hayek
NPI 1336458561
$92,315.52
in general payments reported to CMS, 2019-2025
12 companies · $10K in 2025
The $10K reported for 2025 was more than what 95% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2021: $3,540 · 2022: $7,890 · 2023: $13K · 2024: $57K · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $33K · Consulting Fee: $29K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Travel and Lodging: $5,676 · Food and Beverage: $850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $33,150.00 |
| Consulting Fee | $29,172.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,800.00 |
| Travel and Lodging | $5,675.94 |
| Food and Beverage | $850.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $45,212.22 | 2023-2024 | Inpefa |
| Eli Lilly and Company | $12,366.31 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $11,232.82 | 2022-2025 | |
| Siemens Medical Solutions USA, INC. | $7,000.00 | 2023 | Advia Centaur Xp Analyzer |
| Amgen INC. | $6,300.00 | 2023 | Repatha |
| Sobi, INC | $3,540.00 | 2021 | |
| Roche Diagnostics Corporation | $3,390.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,937.50 | 2024 | Jardiance |
| Pfizer INC. | $1,100.00 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $236.67 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salim Hayek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.